BioCardia Analyst Ratings
BioCardia Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/10/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
07/24/2023 | 890.53% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy |
06/21/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
05/11/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
03/30/2023 | 890.53% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
11/11/2022 | — | Dawson James | Downgrades | Buy → Neutral | |
12/20/2021 | 890.53% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
04/16/2021 | — | Dawson James | Downgrades | Buy → Neutral | |
09/21/2020 | 1165.68% | Alliance Global Partners | → $11.5 | Initiates Coverage On | → Buy |
11/26/2019 | 2321.31% | Brookline Capital | → $22 | Initiates Coverage On | → Buy |
10/10/2019 | 890.53% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
2023年08月10日 | 890.53% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
07/24/2023 | 890.53% | HC Wainwright公司 | $9→$9 | 重申 | 购买→购买 |
2023年6月21日 | 890.53% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
2023年05月11日 | 890.53% | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
03/30/2023 | 890.53% | HC Wainwright公司 | →$9 | 重申 | →购买 |
2022年11月11日 | - | 道森·詹姆斯 | 评级下调 | 购买→中性 | |
12/20/2021 | 890.53% | HC Wainwright公司 | →$9 | 开始承保 | →购买 |
04/16/2021 | - | 道森·詹姆斯 | 评级下调 | 购买→中性 | |
2020/09/21 | 1165.68% | 联盟全球合作伙伴 | →$11.5 | 开始承保 | →购买 |
2019年11月26日 | 2321.31% | 布鲁克林资本 | →$22 | 开始承保 | →购买 |
2019年10月10日 | 890.53% | Maxim集团 | →$9 | 开始承保 | →购买 |
What is the target price for BioCardia (BCDA)?
BioCardia(BCDA)的目标价格是多少?
The latest price target for BioCardia (NASDAQ: BCDA) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $9.00 expecting BCDA to rise to within 12 months (a possible 890.53% upside). 6 analyst firms have reported ratings in the last year.
纳斯达克(BCDA)的最新目标价是由HC Wainwright&Co.于2023年8月10日报道的。这家分析公司将目标价定为9美元,预计BCDA将在12个月内上涨至(可能上涨890.53%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for BioCardia (BCDA)?
最近分析师对BioCardia(BCDA)的评级是多少?
The latest analyst rating for BioCardia (NASDAQ: BCDA) was provided by HC Wainwright & Co., and BioCardia reiterated their buy rating.
分析师对百佳(纳斯达克代码:BCDA)的最新评级由HC Wainwright&Co.提供,百佳重申其买入评级。
When is the next analyst rating going to be posted or updated for BioCardia (BCDA)?
BioCardia(BCDA)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCardia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCardia was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与BioCardia的高管和客户交谈,以及收听收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。BioCardia的上一次评级是在2023年8月10日提交的,所以你应该预计下一次评级将在2024年8月10日左右提供。
Is the Analyst Rating BioCardia (BCDA) correct?
分析师对BioCardia(BCDA)的评级正确吗?
While ratings are subjective and will change, the latest BioCardia (BCDA) rating was a reiterated with a price target of $0.00 to $9.00. The current price BioCardia (BCDA) is trading at is $0.91, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的BioCardia(BCDA)评级被重申,目标价在0.00美元至9.00美元之间。BioCardia(BCDA)目前的交易价格为0.91美元,在分析师的预测范围内。